期刊
CANCER MEDICINE
卷 8, 期 4, 页码 1401-1405出版社
WILEY
DOI: 10.1002/cam4.1980
关键词
BMI; CLL; maintenance; obesity; rituximab
类别
No data are available regarding obesity and outcome in Chronic Lymphocytic Leukemia (CLL). We analyzed 263 patients from the AGMT CLL-8a Mabtenance trial for the impact of obesity. The trial included patients after rituximab-containing induction treatment in first or second line that had achieved at least a PR. A randomization to rituximab maintenance treatment (375mg/m(2) q3 months for 2years) vs observation was performed. In this cohort 22% of the patients (58/263) were classified as obese. The baseline response to induction treatment was inferior in obese patients with a lower CR rate (43.1% vs 60.5% in obese vs non-obese, P=0.018) and with a lower rate of patients achieving MRD negativity after chemoimmunotherapy induction treatment (19.6% vs 35.8%, P=0.02). The PFS outcome of obese patients was significantly worse in the observation group of the trial (24 vs 39months median PFS, P=0.03). However, in the rituximab maintenance group the outcome for obese vs non-obese was not different (P=0.4). In summary, obesity was overall associated with a worse outcome of chemoimmunotherapy induction. However, rituximab maintenance treatment seems to be able to overcome this negative effect.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据